Hepatitis C therapy in non-genotype 1 patients: The near future

Journal of Viral Hepatitis

Volumn 19, Issue 8, 2012, Pages 525-536

  Wartelle Bladou, C ^a   Le Folgoc, G ^b   Bourliere M ^b   Lecomte, L ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b HÔPITAL SAINT JOSEPH   (France)

Author keywords

cyclophilin inhibitors; direct antiviral agent combination; HC; hepatitis C; interferon lambda; nitazoxanide; non genotype 1; NS5A inhibitors; pegylated interferon; protease inhibitors; ribavirin; RNA polymerase inhibitors; silibinin; vitamin D

Indexed keywords

4A PROTEASE INHIBITOR; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; CYCLOPHILIN INHIBITOR; DACLATASVIR; DANOPREVIR; DEB 025; DIRECT ANTIVIRAL AGENT; MERICITABINE; MK 5172; N (2' DEOXY 2' FLUORO 2' METHYL P PHENYL 5' URIDYLYL)ALANINE ISOPROPYL ESTER; NONNUCLEOSIDE INHIBITOR; NONSTRUCTURAL PROTEIN 3 INHIBITOR; NS5A COMPLEX INHIBITOR; NS5B RNA POLYMERASE; NUCLEOTIDE INHIBITOR; PEGINTERFERON ALPHA; RIBAVIRIN; SILIBININ; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG;

GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRAL GENETICS; VIRUS REPLICATION;

ANTIOXIDANTS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOPHILINS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; PROTEASE INHIBITORS; RIBAVIRIN; SILYMARIN;

EID: 84863649118     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01634.x     Document Type: Review

References (53)

1. Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
3. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
4. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
5. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
6. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
7. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; 54: 789-800.
8. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 45.
9. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
10. Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-754.
11. Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-421.
12. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827, 7.
13. Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 1250-1262.
14. Stattermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344-350.
15. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-532.
16. Pham TTT, Ho TD,. An optimal duration of treatment for chronic hepatitis C genotype 6 patients. Hepatology 2011; 54 (Suppl.): 810A-811A.
17. Tangkijvanich P, Komolmit P, Mahachai V, Poovorawan K, Akkarathamrongsin S, Poovorawan Y,. Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study. J Viral Hepat 2012; 19: 423-430.
18. Marcellin P, Cheinquer H, Curescu M, et al. Worldwide experience treating chronic hepatitis C with peginterferon alfa/ribavirin: final results from 7163 naive mono-infected patients enrolled in the large multinational PROPHESYS cohort study. Hepatology 2011; 54 (Suppl.): 824A.
19. Mauss S, Berger F, Vogel M, et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 2012; 50: 441-444.
20. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-889.
21. Silva M, Kasserra C, Gupta A, Treitel M, Hughes E, O'Mara E,. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. APASL Feb 17-20, 2011. Available at:.
22. Benhamou Y, Moussalli J, Ratziu V, et al. Activity of telaprevir or in combination with peginterferon alfa-2a and ribavirin in treatment naive genotype 4 hepatitis C patients. Final results of study C210. Hepatology 2010; 52 (Suppl.): 719A-720A.
23. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J,. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011; 141: 1067-1079.
24. Lin TI, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009; 53: 1377-1385.
25. Barnard RJ, Graham D, Acosta A, et al. MK-5172, a next generation HCV NS3/4A protease inhibitor is active against common resistance associated variants (RAVS) and exhibits cross genotype activity. Global Antiviral Journal 2011; 7 (Suppl. 1), HEP DART 2011; Abstract 108: 99.
26. Membreno FE, Lawitz EJ,. The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis 2011; 15: 611-626.
27. Gish RG, Meanwell NA,. The NS5A replication complex inhibitors: difference makers? Clin Liver Dis 2011; 15: 627-639.
28. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
29. Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006; 43: 761-770.
30. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 1561-1567.
31. Zeuzem S, Arora S, Bacon B, et al. Pegylated interferon lambda shows superior viral response with improved safety and tolerability versus PegIFN alfa-2A in HCV patients (G1/2/3/4): EMERGE phase IIB through week 12. J Hepatol 2011; 54: S538-S539.
32. Everson GT, Gray TE, Hillson JL, et al. Pegylated interferon lambda ameliorates ribavirin-induced anemia in HCV patients by maintaining compensatory erythropoiesis: analysis of emerge phase 2B results through week 12. Hepatology 2011; 54: 993A-994A.
33. Rodriguez-Torres M, Hillson JL, Bacon BR, et al. Safety and efficacy of pegylated interferon lambda compared to pegylated interferon alfa-2A in HCV-infected patients G1/2/3 with compensated cirrhosis: EMERGE phase 2b efficacy and safety results through week 12. Hepatology 2011; 54: 994A.
34. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N,. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011; 17: 5184-5190.
35. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56: 1247-1253.
36. Peltry AS, Fraser IP, O'Mara E, et al. Safety and antiviral activity of MK-5172, a next generation HCV NS3/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants in genotype 1 and 3 HCV infected patients. Hepatology 2011; 54 (Suppl.): 531A.
37. Gane EJ, Rodriguez-Torres M, Nelson DE, et al. Sustained virologic response following RG7128 1500mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non responders. J Hepatol 2010; 52: S16.
38. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PEGIFN/RBV in a phase 2B trial: rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. J Hepatol 2011; 54: S28.
39. Gane EJ, Stedman CA, Hyland RH, et al. ELECTRON: once daily PSI-7977plus RBV in HCV GT1/2/3. J Hepatol 2012; 56: S438-S439.
40. Gane EJ, Stedman C, Hyland RH, et al. Once daily PSI-7977 plus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment naive patients with HCV GT2 or GT3. Hepatology 2011; 54: 377A.
41. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009; 49: 1460-1468.
42. Patel H, Heathcote EJ,. Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3. Gut 2011; 60: 879.
43. Pawlostky JM, Sarin SK, Foster G, et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2or GT3 patients: SVR12 results from VITAL-1 phase 2b study. J Hepatol 2012; 56: S553.
44. Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with the all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor +/- ribavirin in treatment-naive patients with chronic HCV GT1,2, or 3. J Hepatol 2012; 56: S560.
45. Zeuzem S, Arora S, Bacon B, et al. Peginterferon lambda-1A compared to peginterferon alfa-2A in treatment-naive patients with HCV genotypes 2 or 3: first SVR 24 results from EMERGE phase IIB. J Hepatol 2012; 56: S5.
46. Everson G, Cooper C, Hezode C, et al. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir/PEGIFN alfa-2A/RBV in HCV genotype 1 or 4 patients: DAUPHINE week 12 interim analysis. J Hepatol 2012; 56: S466.
47. Wedemeyer H, Jensen D, Herring Jr R, et al. Efficacy and safety of mericitabine in combination with PEG-IFN alfa-2A/RBV in G1/4 treatment naive HCV patients: final analysis from the PROPEL study. J Hepatol 2012; 56: S481.
48. Pockros P, Jensen D, Tsai N, et al. SVR-12 among G1/4 treatment-naive patients receiving mericitabine in combination with PEG-IFN alfa-2A/RBV: interim analysis from the JUMP-C study. J Hepatol 2012; 56: S477-S478.
49. Hassanein T, Nelson DR, Lawitz E, et al. PSI-7977 with PEG/RBV elicits rapid declines in HCV RNA in patients with HCV GT-4 and GT-6. GAJ 2011; 7: 57.
50. Kowdley KV, Lawitz E, Crespo I, et al. ATOMIC: 97% RVR for PSI-7977+PEG/RBV × 12 week regimen in HCV GT1: an end to response-guided therapy? J Hepatol 2012; 56: S1.
51. Hezode C, Hirschfield GM, Ghesquiere W, et al. BMS-790052, A NS5A replication complec inhibitor combined with peginterferon alfa 2a and ribavirin in treatment naive HCV-genotype 1 or 4 patients: phase 2B AI444010 study interim week 12 results. Hepatology 2011; 54: 474A.
52. Ahn J, Flamm SL,. Hepatitis C therapy: other players in the game. Clin Liver Dis 2011; 15: 641-656.
53. Mederacke I, Wedemeyer H,. Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges? Ann Hepatol 2009; 8: 166-168.